Med Life SA · BVB:M
Med Life SA — Q1 2024 Earnings Presentation
17 slides from Med Life SA's earnings presentation, May 10, 2024
Slide 1: Q1 2024 Results Presentation
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharmacies Q1 2024 Results Presentation 10 May 2024 www.medlife.ro / www.medlifeinternational.com
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 3mo 2024 Highlights • • Key messages Outlook 2 AGENDA • Consolidated Statement of Profit and Loss Financial overview • Consolidated Statement of Profit and Loss • Consolidated Statement of Financial Position Financial overview • Consolidated Statement of Financial Position • Consolidated Statement
Slide 4: 3mo 2024 Highlights
3mo 2024 Highlights • Key messages • Outlook 1
Slide 5: Key messages
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies Key messages • Consistent evolution of the financial and operational performance of the Group; • Consolidated pro-forma Turnover of RON 647 million, up by 22% compared to same period last year; • Strong organic
Slide 6: Outlook
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies Outlook Focus on: • optimizing the operational flows and procedures within the group, in order to further leverage the economies of scale and cumulated expertise of each unit; • consolidating profitability marg
Slide 7: Financial overview
Financial overview • Consolidated Statement of Profit and Loss • Consolidated Statement of Financial Position • Consolidated Statement of Cash Flow 2
Slide 8: Consolidated Statement of Profit and Loss
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies Consolidated Statement of Profit and Loss • Consolidated pro-forma Turnover of RON 647m, up by 22% YoY, with a strong evolution in almost all business lines; • Pro-forma EBITDA increased by 33% to RON 99m, reac
Slide 9: Consolidated Statement of Profit and Loss – Pro-forma Revenues
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies Consolidated Statement of Profit and Loss – Pro-forma Revenues From IFRS Revenues to Pro-forma Revenues: • No normalization adjustments from acquisitions, with Personal Genetics SPA completed in April (Sales of
Slide 10: Consolidated Statement of Profit and Loss – Pro-forma EBITDA
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies Consolidated Statement of Profit and Loss – Pro-forma EBITDA From IFRS EBITDA to Pro-forma EBITDA: • No impact in EBITDA pro-forma coming from acquisitions; • ~ RON 1 million one-off expenses adjusted in pro-fo
Slide 11: Consolidated Statement of Profit and Loss – QoQ Evolution
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies Consolidated Statement of Profit and Loss – QoQ Evolution • Gradual improvements in EBITDA levels during 2023 & continuing trend YoY in 2024; • In terms of Revenues, the quarterly trend shows the ability to inc
Slide 12: Consolidated Statement of Profit and Loss – Operational KPIs
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies Consolidated Statement of Profit and Loss – Operational KPIs • Solid growth of 22% in Revenues, out of which 15% organic growth, with almost all business lines continuing their upward trend, highlighting the ex
Slide 13: Consolidated Statement of Profit and Loss – OPEX
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies Consolidated Statement of Profit and Loss – OPEX • Decrease of Operating Expenses as % in Sales with 1.6 p.p. YoY, from 95.4% to 93.8%; • The decrease of the Commodities line as % in Sales in line with last yea
Slide 14: Consolidated Statement of Financial Position
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies Consolidated Statement of Financial Position 14 1. 3mo 2024 Highlights 2. Financial Overview 3. Q&A session
Slide 15: Consolidated Statement of Financial Position – Debt
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies Consolidated Statement of Financial Position – Debt • Net debt to EBITDA ratio decreased from 4.6x to 4.3x, on the back of increased EBITDA levels and margins; • We are committed to continuing the solid busines
Slide 16: Consolidated Statement of Cash Flow
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies Consolidated Statement of Cash Flow • Increased contribution from EBITDA, with net cash from operating activities of RON 106m, 60% higher compared to same period last year 16 1. 3mo 2024 Highlights 2. Financial
Slide 17: Q&A Session Thank you!
Q&A Session Thank you! 17 /